245439-36-5

Basic information

• Product Name: 4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE
• Synonyms: 4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE;4-(3-Bromophenyl)oxane-4-carbonitrile;2H-Pyran-4-carbonitrile, 4-(3-bromophenyl)tetrahydro-
• CAS NO: 245439-36-5
• Molecular Formula: C₁₂H₁₂BrNO
• Molecular Weight: 266.13
• Mol File: 245439-36-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE(245439-36-5)
• EPA Substance Registry System: 4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE(245439-36-5)

Safety Data

• Hazardous Substances Data: 245439-36-5(Hazardous Substances Data)

Usage

Description

4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE, also known as 4-(3-Bromophenyl)oxane-4-carbonitrile, is an organic compound with a molecular structure that features a tetrahydropyran ring and a nitrile functional group. It is characterized by the presence of a bromine atom attached to a phenyl group, which contributes to its unique chemical properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
4-(3-BROMOPHENYL)TETRAHYDROPYRAN-4-CARBONITRILE is used as a key intermediate compound for the synthesis of pyrazolopyridine inhibitors of protein kinase Cθ (PKCθ). These inhibitors play a crucial role in modulating T cell biology, which has significant implications in the development of novel therapeutic strategies for various immune-related disorders and diseases.
The compound's unique structure allows it to interact with specific protein targets, making it a valuable asset in the design and development of new drugs. Its use in the pharmaceutical industry is primarily focused on the creation of PKCθ inhibitors, which can potentially lead to breakthroughs in the treatment of autoimmune diseases, inflammatory conditions, and other T cell-mediated pathologies.

InChI:InChI=1S/C12H12BrNO/c13-11-3-1-2-10(8-11)12(9-14)4-6-15-7-5-12/h1-3,8H,4-7H2

Upstream product

• 31938-07-5 (3-bromophenyl)acetonitrile 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 

Downstream Products

• 278183-71-4 4-[3-(4-Amino-phenyl sulfanyl)-phenyl]-tetrahydro-pyran-4-carbonitrile 
• 1160501-46-1 (4-(3-methyl-5-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)tetrahydro-2H-pyran-4-yl)methanamine 
• 1160500-23-1 (4-(3-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)tetrahydro-2H-pyran-4-yl)methanamine 
• 179420-17-8 4-[3-[4-(2-methylimidazol-1-yl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide 
• 1331755-98-6 C₂₄H₂₈N₂O₄S 
• 1029317-21-2 4-(3-([4-(1-methyl-1H-pyrazol-5-yl)phenyl]thio)phenyl)tetrahydro-2H-pyran-4-carboxamide 
• 1029317-23-4 4-(3-(triisopropylsilylthio)phenyl)tetrahydro-2H-pyran-4-carboxamide 
• 329025-26-5 tetrahydro-4-(3-bromophenyl)-2H-pyran-4-carboxamide 
• 329025-21-0 tetrahydro-4-[3-(4-fluorophenyl)-thio]phenyl-2H-pyran-4-carboxamide 

Relevant articles and documents

BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) C1, Br, I, -CN, -CH3, or -CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

A novel process intermediate, tetrahydro-4-[3-(4-fluorophenyl)thio]phenyl-2H-pyran-4-carboxamide, of the formula: is described, as well as its use in a process of preparing 5-lipoxygenase inhibitors of the formula: which comprises establishing a reaction mixture consisting of: and an electron deficient monocyclic or benzo-fused bicyclic N-heterocycle containing two nitrogen atoms of the formula: ?in an aprotic solvent; in the presence of a carbonate of the formula: (M)2-CO3, where M is an alkali metal, Group 1/Ia element, selected from the group consisting of lithium, Li; sodium,Na; potassium, K; rubidium, Rb; and cesium, Cs; followed by heating of said reaction mixture under a nitrogen atmosphere; whereby there is produced the desired compound of the above-recited formula.